Lymphoma. Immunotherapy. Tweets are my own views
Joined June 2015
- Tweets495
- Following284
- Followers567
- Likes2.2K
The current state of medicine…
A new Clinical Practice article summarizes the classification, evaluation, risk stratification, and management of syncope. History, examination, electrocardiography, and orthostatic blood-pressure measurement identify the cause in most patients.
Read “Syncope” by Rose Anne Kenny, MD, DSc: nej.md/4cjFuVU
Ask AI Companion to provide a summary of this article for your patient. In Spanish.
ALT A flowchart from the Clinical Practice article "Syncope" by Rose Anne Kenny, M.D., D.Sc., that shows the general principles for initial evaluation of all patients after an episode of syncope. The chart includes steps such as suspected syncope, evaluation, history taking, and an ECG. It categorizes causes of syncope as certain or uncertain, leading to risk assessment and further evaluation or treatment.
POLARGO- Good option for some patients in which BiAbs or CART are not an option.
ascopubs.org/doi/10.1200/JCO…
DS5a and DS5b in Hodgkin lymphoma
ashpublications.org/bloodadv…
I don’t remember seen a retraction from NEJM. This is going to be huge…
Avacopan retracted
nejm.org/doi/full/10.1056/NE…
10 years after CAR-T for B-cell lymphomas @MichaelDJain
nejm.org/doi/full/10.1056/NE…
FrontMIND
thelancet.com/journals/lance…
Julio Chavez retweeted
The 19-year drought is over 🇵🇪
Ignacio Buse becomes the first Peruvian finalist on the ATP Tour since Luis Horna at 2007 Vina del Mar - when Buse was aged just 2!
#bitpandahamburgopen
Interesting study and well designed. One weakness is that it started from DLBCL Dx . The real issue is when we don’t have Dx. I’ll have hard time recommending steroids or any therapy if we don’t have Dx
jamanetwork.com/journals/jam…
Excellent analysis
I would add post progression therapies that may be available or not depending of healthcare settings.
PFS is not always OS.
One of the biggest misconceptions in oncology is assuming that delaying progression automatically means patients live longer.
Many strategies consistently improve:
• PFS
• depth of response
• MRD negativity
…but OS often barely moves.
Examples:
• Upfront vs delayed AutoSCT
• Lenalidomide maintenance
• HD melphalan intensification
• Many maintenance strategies in lymphoma
Why?
Because:
• crossover therapies matter
• salvage therapies work
• toxicity matters
• resistant clones survive
• biology evolves
A longer remission is meaningful.
But it is not always a longer life.
The critical question is no longer:
“Did the curve separate?”
The question is:
“What happened to OS?”
#MultipleMyeloma #lymphoma #CART #Hemtwitter
Dr. Fun + G
This is a must read. I do a bit differently. I read the editorial (if available) first. It is usually written by an expert in the field who puts the trial in the perspective of the disease and how it impacts the current landscape. I also read the discussion.
A MUST-READ!
This is probably one of my most important papers where I try to teach how to fish rather than offer fish.
How I Read a Clinical Trial Report?
BG’s primer for Busy Clinicians.
Thank you @JCOOP_ASCO @EthicsdoctorP for the kind invitation. I hope the readers will find this useful.
ascopubs.org/doi/10.1200/OP-…
One of my favorite meetings…It is always great to come back to #Buffalo. Thank you @matt_cortese and Paco for organizing this meeting.
It was great to see friends and colleagues for our @RoswellPark #RoswellParkASHReview26 #heme updates conference hosted with @gotoPER and streamed by @VuMedi! Thank you so much for coming guests and many thanks to speakers & sponsors! #ASH26 #Tandem26
registration.gotoper.com/Ros…
Julio Chavez retweeted
The American Heart Association mourns the passing of the legendary cardiologist Eugene Braunwald, M.D., widely recognized as one of the most influential figures in the history of cardiovascular medicine. Over seven decades, his work reshaped the understanding and treatment of heart disease, leading many to call him the father of modern cardiology.
Braunwald was a lifelong contributor to the American Heart Association, helping advance its research and scientific mission, and was honored with some of the Association’s highest honors for his lasting influence on cardiovascular care and research. His influence extended well beyond his own discoveries, as generations of Association‑supported investigators, clinicians and academic leaders were trained by Braunwald or guided by the clinical trial standards and mentorship models he helped establish.
newsroom.heart.org/news/amer…
Estimados colegas interesados en el mundo de linfomas e imunoterapia. Les invito a atender la revision de lo mejor ASH 2025 (virtual) este sabado Marzo 27
Tendremos expositores de varios paises.
No se lo pierdan!
us02web.zoom.us/meeting/regi…
Interesting take. The growing cost of publishing…
In a challenge to open-access publishers, the Chinese Academy of Sciences, the world’s largest research institution, has told its researchers it plans to stop paying to publish their papers in dozens of international free-to-read journals it regards as too expensive. scim.ag/4tU6qD5
Outstanding best of #ASH25 summary by Dr Esther Obeng from #emory @EmoryUniversity …If you missed, I hope you can watch it virtually later…
